These possibilities, together with the well-established effect of IL1-targeting in improving cancer prognosis (Briukhovetska et al., 2021; Cristofari and Lingner, 2006; Mantovani et al., 2019; Mantovani et al., 2018) underline the need for further work to attain a deeper understanding of telomere-sensitive IL1 signalling in the TME. The gene discussed is IL1A; the disease is cancer.